Clinical Trials Search
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses and Treatment Intensification of a Vaccine-Based Immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for Advanced Non-Small Cell Lung Cancer and Metastatic Triple-Negative Breast Cancer
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with advanced non-small cell lung cancer and metastatic triple-negative breast cancer.
Primary Objective(s): Phase 1A - To assess safety and tolerability of increasing dose levels of VBIR-2. - To characterize the dose limiting toxicities (DLTs) and overall safety profile of escalated doses of VBIR-2. - To assess safety and tolerability at increasing dose levels of VBIR-2 components in successive cohorts of patients in order to estimate the Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose RP2D)/schedule. Secondary Objective(s): - To evaluate the immune response elicited by VBIR-2 to the 3 selected tumor-antigens. - To evaluate the PK of tremelimumab and of anti-PD-1 (PF-06801591) after SC administration. - To evaluate the anti-drug antibody (ADA) response of tremelimumab and anti-PD-1 (PF-06801591) after SC administration with the other components. - To evaluate the pharmacodynamic (PD) effects of VBIR-2 by tumor type. - To document any preliminary evidence of anti-tumor activity. Tertiary/Exploratory Objective(s): - To collect banked biospecimens for exploratory research, unless prohibited by local regulations or ethics committee decision.
AdC68 (); CP-675,206 (tremelimumab); PF-06801591 (); pDNA (); tremelimumab ()